Does Varenicline Worsen Psychiatric Symptoms in Patients With Schizophrenia or Schizoaffective Disorder? A Review of Published Studies

Objective: To review published cases and prospective studies describing the use of varenicline in patients with schizophrenia and schizoaffective disorder.

Data Sources: PubMed, PsychINFO, and the Cochrane Database were searched in July 2011 using the key words schizophrenia, schizoaffective disorder, psychosis, positive symptoms, negative symptoms, aggression, hostility, suicidal ideation AND varenicline to identify reports published between January 2006 and July 2011 in English.

Study Selection: Five case reports, 1 case series, 1 retrospective study, 10 prospective studies (17 publications), and 1 meeting abstract describing the use of varenicline in patients with schizophrenia or schizoaffective disorder were identified. Review articles and articles describing findings other than the use of varenicline in patients with schizophrenia or schizoaffective disorder were excluded. Thirteen reports were included in the final analysis.

Data Extraction: Information on each study’s patient population, age, diagnosis, medication treatment, tobacco use history, adverse effects, and outcome was collected from the published reports.

Results: Of the 260 patients with schizophrenia or schizoaffective disorder who received varenicline in these published reports, 13 patients (5%) experienced the onset or worsening of any psychiatric symptom, although 3 of the 13 patients experienced a very brief negative effect after 1 dose. No patients experienced suicidal ideation or suicidal behaviors.

Conclusions: Published reports suggest that, in most stable, closely monitored patients with schizophrenia or schizoaffective disorder, varenicline treatment is not associated with worsening of psychiatric symptoms. Current, prospective studies are assessing effectiveness and further assessing safety in this population.

J Clin Psychiatry 2012;73(8):e1039-e1047

© Copyright 2012 Physicians Postgraduate Press, Inc.

Submitted: September 21, 2011; accepted February 16, 2012 (doi:10.4088/JCP.11r07410).

Corresponding author: Joseph M. Cerimele, MD, Department. of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1959 NE Pacific St, Box 356560, Seattle, WA 98195 (cerimele@uw.edu).